Could a common liver drug help fight severe COVID-19?
NCT ID NCT04374461
First seen Jan 02, 2026 · Last updated May 20, 2026 · Updated 22 times
Summary
This study tests whether N-acetylcysteine, a drug already used for liver protection and lung mucus thinning, can help severe COVID-19 patients by boosting their immune system. About 48 adults with confirmed COVID-19 who are in intensive care or on a ventilator (Arm A) or need extra oxygen (Arm B) will receive the drug. The goal is to see if it helps them leave the ICU or come off a ventilator.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.